Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Beyza Dönmüş, Sinan Ünal, Fatma Ceren Kirmizitaş & Nelisa Türkoğlu Laçin. (2021) Virus-associated ribozymes and nano carriers against COVID-19. Artificial Cells, Nanomedicine, and Biotechnology 49:1, pages 204-218.
Read now
Read now
Vicente Soriano, Pablo Labarga, José V. Fernandez-Montero, Carmen de Mendoza, Laura Benítez-Gutiérrez, José M. Peña & Pablo Barreiro. (2017) Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opinion on Drug Metabolism & Toxicology 13:8, pages 807-816.
Read now
Read now
Vincent Soriano, Pablo Labarga, Carmen de Mendoza, José V Fernández-Montero, Isabella Esposito, Laura Benítez-Gutiérrez, José M Peña & Pablo Barreiro. (2016) New hepatitis C therapies for special patient populations. Expert Opinion on Pharmacotherapy 17:2, pages 217-229.
Read now
Read now
Michael A Smith & Alice Lim. (2015) Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Design, Development and Therapy 9, pages 6083-6094.
Read now
Read now
Isabella Esposito, Pablo Labarga, Pablo Barreiro, José V Fernandez-Montero, Carmen de Mendoza, Laura Benítez-Gutiérrez, José M Peña & Vicente Soriano. (2015) Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects. Expert Opinion on Drug Safety 14:9, pages 1421-1434.
Read now
Read now
Yousef Fazel, Brian Lam, Pegah Golabi & Zobair Younossi. (2015) Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Expert Opinion on Drug Safety 14:8, pages 1317-1326.
Read now
Read now
Articles from other publishers (36)
Sara I. Aboras, Mohamed A. Korany, Ahmed F. El‐Yazbi, Marwa A. A. Ragab & Heba H. Abdine. (2022) In‐depth investigation of the Silymarin effect on the pharmacokinetic parameters of sofosbuvir, GS‐331007 and ledipasvir in rat plasma using LC–MS. Biomedical Chromatography 36:9.
Crossref
Crossref
Xiaoyan Chu, Grace Hoyee Chan, Robert Houle, Meihong Lin, Jocelyn Yabut & Christine Fandozzi. (2022) In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models. The AAPS Journal 24:3.
Crossref
Crossref
Dipy M. Vasa, Zainab Bakri, Maureen D. Donovan, Lauren A. O’Donnell & Peter L. D. Wildfong. (2021) Evaluation of Ribavirin–Poloxamer Microparticles for Improved Intranasal Absorption. Pharmaceutics 13:8, pages 1126.
Crossref
Crossref
Maria Giovanna Quaranta, Stefano Rosato, Luigina Ferrigno, Daniela Caterina Amoruso, Monica Monti, Paola Di Stefano, Roberto Filomia, Elisa Biliotti, Guglielmo Migliorino, Francesco Paolo Russo, Elisabetta Degasperi, Liliana Chemello, Giuseppina Brancaccio, Pierluigi Blanc, Marco Cannizzaro, Francesco Barbaro, Giulia Morsica, Anna Licata & Loreta A Kondili. (2019) Real-Life use of Elbasvir/Grazoprevir in Adults and Elderly Patients: A Prospective Evaluation of Comedications used in the PITER Cohort. Antiviral Therapy 25:2, pages 73-81.
Crossref
Crossref
Xinran Zou, Jing Wu, Jiaqi Gu, Li Shen & Lingxiang Mao. (2019) Application of Aptamers in Virus Detection and Antiviral Therapy. Frontiers in Microbiology 10.
Crossref
Crossref
Daniel Esteban Pino Marín, Pedro Amariles, Jaime Alberto Peláez Alvárez, Gloria Priscilla Alvárez Osorio & Juliana González Ceballos. (2019) Aproximación para establecer y evaluar la relevancia clínica de las interacciones medicamentosas en el tratamiento de pacientes infectados con virus de hepatitis C, revisión estructurada (actualización 2015 – 2017). Revista Colombiana de Gastroenterología 34:2, pages 159-176.
Crossref
Crossref
Jorge Soares, António Ferreira, André Silva-Pinto, Francisco Almeida, Carmela Piñeiro, Rosário Serrão & António Sarmento. (2019) The Influence of Antiretroviral Therapy on Hepatitis C Virus Viral Load and Liver Fibrosis in Human Immunodeficiency Virus-Coinfected Patients: An Observational Study. Intervirology 62:5-6, pages 182-190.
Crossref
Crossref
Ting-Chun Hung, Alagie Jassey, Chien-Ju Lin, Ching-Hsuan Liu, Chun-Ching Lin, Ming-Hong Yen & Liang-Tzung Lin. (2018) Methanolic Extract of Rhizoma Coptidis Inhibits the Early Viral Entry Steps of Hepatitis C Virus Infection. Viruses 10:12, pages 669.
Crossref
Crossref
Yankun YuFeng LiuLiuming HeSeeram RamakrishnaMonica ZhengLei BuYing Xu. (2018) Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Bradycardiac Effects Caused by Co-Administration of Sofosbuvir and Amiodarone. ASSAY and Drug Development Technologies 16:4, pages 222-229.
Crossref
Crossref
Moisés Uriarte-Pinto, Herminia Navarro-Aznarez, Natalia De La Llama-Celis, Piedad Arazo-Garcés, Ana María Martínez-Sapiña & María Reyes Abad-Sazatornil. (2018) Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world. International Journal of Clinical Pharmacy 40:3, pages 608-616.
Crossref
Crossref
Fiona Marra, Christoph Höner zu Siederdissen, Saye Khoo, David Back, Michael Schlag, Sivi Ouwerkerk‐Mahadevan, Ceyhun Bicer, Isabelle Lonjon‐Domanec, Wolfgang Jessner, Maria Beumont‐Mauviel, Ronald Kalmeijer & Markus Cornberg. (2018) Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. British Journal of Clinical Pharmacology 84:5, pages 961-971.
Crossref
Crossref
Sanhua Wei, Yingfeng Lei, Jie Yang, Xiaoyan Wang, Fang Shu, Xin Wei, Fang Lin, Bin Li, Ying Cui, Hai Zhang & Sanhua Wei. (2018) Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes. Vaccine 36:17, pages 2273-2281.
Crossref
Crossref
Asmaa M. Abdel-Aziz, Mohamed A. Ibrahim, Azza A. El-Sheikh, Maha Y. Kamel, Nagwa M. Zenhom, Salam Abdel-Raheim & Hisham Abdelhaleem. (2018) Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis. Journal of Clinical and Experimental Hepatology 8:1, pages 15-22.
Crossref
Crossref
Paola Carrai, Cristina Morelli, Gabriella Cordone, Antonietta Romano, Mariarosa Tamé, Raffaella Lionetti, Giada Pietrosi, Ilaria Lenci, Guido Piai, Francesco Paolo Russo, Carmine Coppola, Mario Melazzini, Simona Montilla, Luca Pani, Sandra Petraglia, Pierluigi Russo, Maria Paola Trotta, Silvia Martini & Pierluigi Toniutto. (2017) The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Transplant International 30:12, pages 1253-1265.
Crossref
Crossref
Sabina Steiner, Nikola Raguž-Lučić & Damir Erceg. 2017. Update on Hepatitis C. Update on Hepatitis C.
Joseph P. Rindone & Chadwick K. Mellen. (2017) Reduction in warfarin effect associated with sofosbuvir–velpatasvir. American Journal of Health-System Pharmacy 74:17, pages 1308-1311.
Crossref
Crossref
Mohamad Shebley, Jinrong Liu, Olga Kavetskaia, Jens Sydor, Sonia M. de Morais, Volker Fischer, Marjoleen J.M.A. Nijsen & Daniel A.J. Bow. (2017) Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir. Drug Metabolism and Disposition 45:7, pages 755-764.
Crossref
Crossref
Jessica Cusato, Lucio Boglione, Amedeo De Nicolò, Chiara Simona Cardellino, Chiara Carcieri, Giuseppe Cariti, Giovanni Di Perri & Antonio D'Avolio. (2017) Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. Pharmacogenomics 18:7, pages 607-611.
Crossref
Crossref
Douglas D. DeCarolis, Yi-Chieh Chen & Anders D. Westanmo. (2017) Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin: Twelve-Week Post-treatment Follow-up. Annals of Pharmacotherapy 51:5, pages 439-440.
Crossref
Crossref
Hugo Monrroy, Jenniffer Angulo, Karla Pino, Pilar Labbé, Juan Francisco Miquel, Marcelo López-Lastra & Alejandro Soza. (2017) Detection of high biliary and fecal viral loads in patients with chronic hepatitis C virus infection. Gastroenterología y Hepatología 40:5, pages 339-347.
Crossref
Crossref
Hugo Monrroy, Jenniffer Angulo, Karla Pino, Pilar Labbé, Juan Francisco Miquel, Marcelo López-Lastra & Alejandro Soza. (2017) Detection of high biliary and fecal viral loads in patients with chronic hepatitis C virus infection. Gastroenterología y Hepatología (English Edition) 40:5, pages 339-347.
Crossref
Crossref
Loreta A. Kondili, Giovanni Battista Gaeta, Donatella Ieluzzi, Anna Linda Zignego, Monica Monti, Andrea Gori, Alessandro Soria, Giovanni Raimondo, Roberto Filomia, Alfredo Di Leo, Andrea Iannone, Marco Massari, Romina Corsini, Roberto Gulminetti, Alberto Gatti Comini, Pierluigi Toniutto, Denis Dissegna, Francesco Paolo Russo, Alberto Zanetto, Maria Grazia Rumi, Giuseppina Brancaccio, Elena Danieli, Maurizia Rossana Brunetto, Liliana Elena Weimer, Maria Giovanna Quaranta, Stefano Vella & Massimo Puoti. (2017) Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLOS ONE 12:2, pages e0172159.
Crossref
Crossref
Sarah Talavera Pons, Anne Boyer, Geraldine Lamblin, Philip Chennell, François‐Thibault Châtenet, Carine Nicolas, Valérie Sautou & Armand Abergel. (2016) Managing drug–drug interactions with new direct‐acting antiviral agents in chronic hepatitis C. British Journal of Clinical Pharmacology 83:2, pages 269-293.
Crossref
Crossref
Ryoichi Miyazaki, Kyoko Miyagi & Rika Kawamura. (2017) Treatment of hepatitis C virus infections in hemodialysis patients at our hospital and future prospects. Nihon Toseki Igakkai Zasshi 50:5, pages 281-287.
Crossref
Crossref
Douglas D. DeCarolis, Anders D. Westanmo, Yi-Chie Chen, Amanda L. Boese, Mary A. Walquist & Thomas S. Rector. (2016) Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin. Annals of Pharmacotherapy 50:11, pages 909-917.
Crossref
Crossref
Daniel C. Millard, Christopher J. Strock, Coby B. Carlson, Natsuyo Aoyama, Krisztina Juhasz, Tom A. Goetze, Sonja Stoelzle-Feix, Nadine Becker, Niels Fertig, Craig T. January, Blake D. Anson & James D. Ross. (2016)
Identification of Drug?Drug Interactions
In Vitro
: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes
. Toxicological Sciences 154:1, pages 174-182.
Crossref
Crossref
Ryoichi Miyazaki & Kyoko Miyagi. (2016) Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis. Therapeutic Apheresis and Dialysis 20:5, pages 462-467.
Crossref
Crossref
Jérôme Dumortier, Vincent Leroy, Christophe Duvoux, Victor de Ledinghen, Claire Francoz, Pauline Houssel‐Debry, Sylvie Radenne, Louis d'Alteroche, Claire Fougerou‐Leurent, Valérie Canva, Vincent di Martino, Filomena Conti, Nassim Kamar, Christophe Moreno, Pascal Lebray, Albert Tran, Camille Besch, Alpha Diallo, Alexandra Rohel, Emilie Rossignol, Armand Abergel, Danielle Botta‐Fridlund, Audrey Coilly, Didier Samuel, Jean‐Charles Duclos‐Vallée & Georges‐Philippe Pageaux. (2016) Sofosbuvir‐based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. Liver Transplantation 22:10, pages 1367-1378.
Crossref
Crossref
José Vicente Fernández-Montero & Vicente Soriano. (2016) SOLAR-2: the sun also rises for cirrhotics. The Lancet Infectious Diseases 16:6, pages 624-625.
Crossref
Crossref
Eric Chow, Zainab Shahid, Elton T. SmithJr.Jr., Michal Kamionek & Saad Z. Usmani. (2016) Successful Treatment of Hepatitis C Infection While Receiving Concurrent Chemotherapy for AL Amyloidosis. Clinical Lymphoma Myeloma and Leukemia 16:4, pages 237-239.
Crossref
Crossref
Sophie Renet, Marie-Camille Chaumais, Teresa Antonini, Alexandre Zhao, Laure Thomas, Arnaud Savoure, Didier Samuel, Jean-Charles Duclos-Vallée & Vincent Algalarrondo. (2015) Extreme Bradycardia After First Doses of Sofosbuvir and Daclatasvir in Patients Receiving Amiodarone: 2 Cases Including a Rechallenge. Gastroenterology 149:6, pages 1378-1380.e1.
Crossref
Crossref
Vanessa Costilla, Neha Mathur & Julio A. Gutierrez. (2015) Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment. Clinics in Liver Disease 19:4, pages 641-656.
Crossref
Crossref
Isabelle Poizot-Martin, Alissa Naqvi, V?ronique Obry-Roguet, Marc-Antoine Valantin, Lise Cuzin, Eric Billaud, Antoine Cheret, David Rey, Christine Jacomet, Claudine Duvivier, Pascal Pugliese, Pierre Pradat & Laurent Cotte. (2015) Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. PLOS ONE 10:10, pages e0141164.
Crossref
Crossref
J Florian, P Mishra, V Arya, P Harrington, S Connelly, KS Reynolds & V Sinha. (2015) Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. Clinical Pharmacology & Therapeutics 98:4, pages 394-402.
Crossref
Crossref
Clair M. Gardiner. (2015) NK cell function and receptor diversity in the context of HCV infection. Frontiers in Microbiology 6.
Crossref
Crossref
Leonie Meemken, Nikola Hanhoff, Alice Tseng, Stefan Christensen & Anton Gillessen. (2015) Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy. Annals of Pharmacotherapy 49:7, pages 796-807.
Crossref
Crossref